Please be aware that all clinical studies at TUCC are voluntary, meaning that patients may drop out of the study at any time. All study procedures and medication will be provided to patients free of charge.
Click on a study below to review its description. Click here to request additional information from the TUCC Clinical Research Department.
- Bladder Cancer
TUCC is currently enrolling patients in two different clinical trials for the treatment of bladder cancer:
- A Phase II, open-label study evaluating DN24-02 as adjuvant therapy in subjects with high risk HER2+ urothelial carcinoma. This study incorporates a novel immunotherapy given intravenously.
- A Phase II, randomized, open label, parallel ARM study to evaluate the safety and efficacy of rAd-IFN/Syn 3 following intravesical administration in subjects with high grade, BCG refractory or relapsed non-muscle invasive bladder cancer. This research study evaluates the effectiveness and safety of two doses of Instiladrin, given into the bladder on up to four occasions.
Please call 303.421.5783 to learn more about this study.
- Kidney Cancer
TUCC is currently enrolling patients in an international phase III randomized trial of autologous dendritic cell immunotherapy (AGS-003) plus standard treatment of advanced renal cell carcinoma (ADAPT).
Main inclusion criteria are diagnosis or clinical signs of advanced RCC and are scheduled for unilateral or partial nephrectomy. Main exclusion criteria are prior immunotherapy, chemotherapy, hormona or investigational therapy for renal cell carcinoma and prior history of malignancy other than RCC within the preceding three years, except for adequately treated in situ carcinomas or non-melanoma skin cancer.
Call 303.421.5783 to learn more about this study.
- Osteonecrosis of the Jaw (ONJ)
TUCC is currently enrolling patients in an ONJ case registry. The purpose of this registry is to describe the natural history of positively-adjudicated ONJ in subjects with cancer with an observation period of five years.
Patient Inclusion Criteria:
- Adult (≥18 years of age) with diagnosis of cancer.
- Newly diagnosed, positively-adjudicated ONJ.
- Willing to provide access to previous and future medical and dental information.
Patient Exclusion Criteria:
- History of radiation to the maxillofacial area administered for therapeutic intent in the treatment of cancer.
Please call 303.421.5783 to learn more about this study.
- Prostate Cancer
TUCC is currently enrolling patients in seven different clinical trials for the treatment of prostate cancer.
- A Phase II study of Abiraterone Acetate plus Prednisone in subjects with advanced prostate cancer without radiographic evidence of metastatic disease. This approved medication will be studied to possibly offset the progression of non-metastatic prostate cancer in patients currently on hormonal therapy with a rising PSA.
- A Phase II efficacy and safety study of MDV3100 vs. Bicalutamide in castrate men with metastatic prostate cancer.
- Study to evaluate new or worsening lens opacifications in subjects with nonmetastatic prostate cancer receiving Denosumab for bone loss due to androgen deprivation therapy. This is a clinical trial that incorporates an approved bone loss prevention medication.
- An international, open label, randomized study assessing the safety and efficacy of a monthly dosing regimen of Ozarelix vs. Goserlin Depot (Zoladex) in men with prostate cancer. Men must be 45 years of age or older and have not had any previous hormonal therapy.
- A Phase II multi-center prospective open label, 2-dose level clinical trial studying the safety and efficacy of an injection of NX-1207 for the treatment of low risk, localized (T1c) prostate cancer.
- Phase II, double blind, efficacy and safety study of Enzalutamide vs. Bicalutamide in men with prostate cancer who have failed primary androgen deprivation therapy.
- A randomized, double-blind, Phase III Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer. Patients must have a progression of their prostate cancer during hormonal therapy. Patients cannot have metastatic disease to any other organ than lymph nodes and/or bone and must not have received previous immunotherapy or chemotherapy for prostate cancer. Learn more about this trial at www.ContinueYourFight.com.
Please call 303.421.5783 to learn more about these studies.
